arrow
A

Alan S. Gamis

university of missouri kansas city
H指数:55
被引数:9,804

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.

联合抑制Menin和MEK以靶向预后不良的KMT2A重排RAS通路突变急性髓系白血病

2026-05-070
OAAI
Proof-of-concept study for the detection of somatic structural variant driver alterations using HiFi long-read sequencing in a pediatric leukemia cohort

使用高保真长读长测序检测儿科白血病队列中体细胞结构变异驱动突变的可行性研究

2026-04-090
OA
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease

分子风险标志物定义唐氏综合征髓系白血病的复发风险,超越可测残留病灶

2025-10-240
OAAI
Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia

急性髓系白血病的表观基因组学诊断与预后

2025-07-290
OAAI
Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome

治疗强化并未改善唐氏综合征伴髓系白血病患儿的预后

BLOOD
IF23.1
2024-11-050
PRE
Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia

快速长读长表观基因组学对急性髓系白血病的诊断与预后

BLOOD
IF23.1
2024-11-050
PRE
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials
2024-08-010
OAAI
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis

AML中IDH突变的特征和预后影响: COG,SWOG和ECOG分析

2023-10-0218
OAAI
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
2023-02-2330
OAAI
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
2022-09-1921
OAAI
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy
2022-09-0122
OAAI
CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
2021-11-307
OAAI